{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T16:27:39Z","timestamp":1772641659995,"version":"3.50.1"},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The management of metastatic colorectal cancer (mCRC) in late-line settings remains a significant clinical challenge. The SUNLIGHT trial, which investigated the combination of trifluridine-tipiracil (FTD-TPI) and bevacizumab, reported a median progression-free survival (PFS) of 5\u2009months and an objective response rate (ORR) of 6.3%. This phase II study was conducted to evaluate the potential of combining anlotinib with FTD-TPI as a third-line treatment strategy in patients with refractory mCRC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this open-label, single-arm phase II study, mCRC patients who had experienced disease progression following at least two prior standard treatment regimens were enrolled. Participants received a combination of anlotinib (12\u2009mg, PO, QD, days 1-14, q3w) and FTD-TPI (35\u2009mg\/m2, PO, BID, days 1-5, q2w). The primary endpoint was the ORR. Secondary endpoints included disease control rate (DCR), PFS, overall survival (OS) and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>As of May 30, 2025, twenty-one patients with mCRC were enrolled in this study. The median age was 62\u2009years, with 71.4% male participants. Among the 20 evaluable patients, 2 achieved a partial response (PR), 16 had stable disease (SD) at the first evaluation. The ORR was 10.0% (2\/20), and the DCR reached 90.0% (18\/20). Based on Kaplan\u2013Meier estimates, the median PFS was 5.6\u2009months. The most common grade \u22653 treatment emergent adverse event (TEAEs) were neutropenia (25%) and thrombocytopenia (5%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The combination of anlotinib and FTD-TPI demonstrated promising efficacy and a manageable safety profile, supporting its potential as a favorable late-line treatment option for patients with refractory mCRC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>ClinicalTrials.gov Identifier<\/jats:title>\n                    <jats:p>ChiCTR2400079535.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag019","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T12:56:35Z","timestamp":1771505795000},"source":"Crossref","is-referenced-by-count":0,"title":["Anlotinib in combination with trifluridine-tipiracil in patients with refractory metastatic colorectal cancers: a phase II, single arm study"],"prefix":"10.1093","volume":"31","author":[{"given":"Qing","family":"Liu","sequence":"first","affiliation":[{"name":"Cancer Center, Shanghai Key Laboratory of Oncology Target Discovery and Antibody Drug Development, Zhongshan Hospital, Fudan University , Shanghai,","place":["China"]},{"name":"Department of Medical Oncology, Zhongshan Hospital, Fudan University , Shanghai,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Cancer Center, Shanghai Key Laboratory of Oncology Target Discovery and Antibody Drug Development, Zhongshan Hospital, Fudan University , Shanghai,","place":["China"]},{"name":"Department of Medical Oncology, Zhongshan Hospital, Fudan University , Shanghai,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengling","family":"Liu","sequence":"additional","affiliation":[{"name":"Cancer Center, Shanghai Key Laboratory of Oncology Target Discovery and Antibody Drug Development, Zhongshan Hospital, Fudan University , Shanghai,","place":["China"]},{"name":"Department of Medical Oncology, Zhongshan Hospital, Fudan University , Shanghai,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Peng","sequence":"additional","affiliation":[{"name":"Cancer Center, Shanghai Key Laboratory of Oncology Target Discovery and Antibody Drug Development, Zhongshan Hospital, Fudan University , Shanghai,","place":["China"]},{"name":"Department of Medical Oncology, Zhongshan Hospital, Fudan University , Shanghai,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojing","family":"Xu","sequence":"additional","affiliation":[{"name":"Cancer Center, Shanghai Key Laboratory of Oncology Target Discovery and Antibody Drug Development, Zhongshan Hospital, Fudan University , Shanghai,","place":["China"]},{"name":"Department of Medical Oncology, Zhongshan Hospital, Fudan University , Shanghai,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiyi","family":"Yu","sequence":"additional","affiliation":[{"name":"Cancer Center, Shanghai Key Laboratory of Oncology Target Discovery and Antibody Drug Development, Zhongshan Hospital, Fudan University , Shanghai,","place":["China"]},{"name":"Department of Medical Oncology, Zhongshan Hospital, Fudan University , Shanghai,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8604-6311","authenticated-orcid":false,"given":"Tianshu","family":"Liu","sequence":"additional","affiliation":[{"name":"Cancer Center, Shanghai Key Laboratory of Oncology Target Discovery and Antibody Drug Development, Zhongshan Hospital, Fudan University , Shanghai,","place":["China"]},{"name":"Department of Medical Oncology, Zhongshan Hospital, Fudan University , Shanghai,","place":["China"]},{"name":"Center of Evidence-based Medicine, Fudan University , Shanghai,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,2,20]]},"reference":[{"key":"2026030406384916400_oyag019-B1","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","article-title":"Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer","volume":"388","author":"Prager","year":"2023","journal-title":"N Engl J Med"},{"key":"2026030406384916400_oyag019-B2","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1001\/jamaoncol.2018.3039","article-title":"Effect of anlotinib as a Third-Line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 Phase 3 Randomized Clinical Trial","volume":"4","author":"Han","year":"2018","journal-title":"JAMA Oncol"},{"key":"2026030406384916400_oyag019-B3","doi-asserted-by":"publisher","first-page":"5290","DOI":"10.1158\/1078-0432.CCR-22-1903","article-title":"Anlotinib plus epirubicin followed by anlotinib maintenance as first-line treatment for advanced soft-tissue sarcoma: an open-label, single-arm, phase II trial","volume":"28","author":"Wang","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2026030406384916400_oyag019-B4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.gene.2018.02.026","article-title":"Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFR\u03b2 and FGFR1","volume":"654","author":"Lin","year":"2018","journal-title":"Gene"},{"key":"2026030406384916400_oyag019-B5","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.3892\/ol.2020.11685","article-title":"Anlotinib as a molecular targeted therapy for tumors","volume":"20","author":"Gao","year":"2020","journal-title":"Oncol Lett"},{"key":"2026030406384916400_oyag019-B6","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13045-018-0664-7","article-title":"Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development","volume":"11","author":"Shen","year":"2018","journal-title":"J Hematol Oncol"},{"key":"2026030406384916400_oyag019-B7","doi-asserted-by":"publisher","first-page":"e1693","DOI":"10.1002\/onco.13857","article-title":"Anlotinib monotherapy for refractory metastatic colorectal cancer: a double-blinded, placebo-controlled, randomized phase III trial (ALTER0703)","volume":"26","author":"Chi","year":"2021","journal-title":"Oncologist"},{"key":"2026030406384916400_oyag019-B8","doi-asserted-by":"publisher","first-page":"LBA3502","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA3502","article-title":"Anlotinib versus bevacizumab added to standard first-line chemotherapy among patients with RAS\/BRAF wild-type, unresectable metastatic colorectal cancer: a multicenter, prospective, randomised, phase 3 clinical trial (ANCHOR trial)","volume":"43","author":"Ding","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026030406384916400_oyag019-B9","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41392-022-00922-2","article-title":"Colorectal liver metastasis: molecular mechanism and interventional therapy","volume":"7","author":"Zhou","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"2026030406384916400_oyag019-B10","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.cmet.2019.06.001","article-title":"Macrophages and metabolism in the tumor microenvironment","volume":"30","author":"Vitale","year":"2019","journal-title":"Cell Metab"},{"key":"2026030406384916400_oyag019-B11","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.semcancer.2017.08.001","article-title":"Mechanisms that drive inflammatory tumor microenvironment, tumor heterogeneity, and metastatic progression","volume":"47","author":"Yang","year":"2017","journal-title":"Semin Cancer Biol"},{"key":"2026030406384916400_oyag019-B12","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/s41591-023-02240-8","article-title":"Codon-specific KRAS mutations predict survival benefit of trifluridine\/tipiracil in metastatic colorectal cancer","volume":"29","author":"van de Haar","year":"2023","journal-title":"Nat Med"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag019\/67024287\/oyag019.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/3\/oyag019\/67024287\/oyag019.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/3\/oyag019\/67024287\/oyag019.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T11:38:52Z","timestamp":1772624332000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag019\/8493215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2,5]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag019","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,2,5]]},"article-number":"oyag019"}}